AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02904668 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: self-managmeent program
Description: One session was a session supervised by a physical therapist in the Faculty of Health Sciences. The program contents were educative information about chronic neck pain and healthy lifestyle habits (application of local heat/cold, and sleeping face down, using correct sitting posture, alternating body position, and using correct lifting technique (...), which were complemented by a problem-based session.
Study NCT01064531 — intervention group
Intervention type: DEVICE
Intervention: MIS Femoral Neck Stem implant
Study NCT04999930 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aerochamber
Description: efficacy and patients satisfaction
Study NCT00887328 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tissue Plasminogen Activator (Alteplase)
Description: 0.9 mg/kg up to a maximum of 90mg, intravenous, 10% as bolus and the remainder over 1 hour
Study NCT00887328 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo provided as 50mg lyophilised powder to be reconstituted with sterile water in glass vials indistinguishable from active drug
Study NCT03344978 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cardboard Cot Care
Description: Infant maintained in reflective film-lined cot for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. Infant may be moved to incubator or radiant warmer. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
Study NCT03344978 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Incubator Care
Description: Infant maintained in standard incubator for a period of 24 hours. Axillary temperatures will be taken at 1 hour, 6 hours, and 24 hours after randomization. If temperatures found \< 36° C. at any time, an additional blanket and hat will be added to infant to improve temperature. All other care will be standard of care at University Teaching Hospital, including warm delivery rooms, immediate drying, postponed bathing and weighing, early and exclusive breastfeeding, and Kangaroo Mother Care as continuously as possible.
Study NCT02728011 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Scientific Brain Training (SBT)
Description: Cognitive training
Study NCT02728011 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Tetris
Study NCT02098421 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Use of oxytocin while the Foley bulb is in place
Study NCT03476343 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GE OPTIMA MR430s with HDx/GE Electronics
Description: MRI scan
Study NCT04108559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Kinesiologic Tape Group
Description: A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures.The kinesiologic tape will be prepared individually for each patient; it will be cut into three equal strips (approximately 1.6 cm in width) and placed between the clavicle and the tragus-commissura line. The patients will be invited after one week for removing the sutures.
Study NCT04108559 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Drain Group
Description: A mucoperiosteal flap will be raised, a conventional rotary handpiece will be used under irrigation for removing the third molar.Primary wound closure will be accomplished using 3-0 silk sutures. A plastic non-customised drain tube (2-cm long, 2-mm diameter) will be inserted into a vertical incision between the first and second molars and sutured to the vestibular mucosa. The patients will be invited after one week for removing the sutures.
Study NCT04108559 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control Group
Description: Routine third molar extraction will be performed. No extra procedures will be done after surgery.
Study NCT03083626 — intervention group
Intervention type: OTHER
Intervention: Cold pressor test
Description: The cold pressor test is a procedure used for examining pain threshold and tolerance by subjects placing their forearm in an ice bath. Each participant will take the CPT at 1 °C, 5°C, and 9°C. The first CPT will always be at 1 °C, to ensure participants tolerate the ice bath at the standard temperature. The order of the subsequent CPT at 5°C and 9°C, will be randomized to control for differential carry over effects. Participants will be instructed to say Pain when pain is initially detected (threshold). Then they will be asked to keep the immersed limb in the container until the pain can no longer be tolerated and say Stop and remove the arm from the water when tolerance is reached.
Study NCT00682214 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: Drug: Cholecalciferol 60,000 IU sachet and calcium carbonate Oral cholecalciferol (vitamin D)60,000 IU weekly along with daily oral dose of 1 gm calcium carbonate for first two months followed by 1 gm of elemental calcium in form of calcium carbonate daily cholecalciferol (vitamin D)60,000 IU per month for the next four months
Study NCT00682214 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose placebo
Description: Lactose placebo granules in identical sachet given weekly and two lactose tablets for first two months followed one sachet of placebo granules every month and two tablets of lactose containing placebo tablets taken daily for next four months
Study NCT02555020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Allocated to Carbohydrated group
Description: Patients received 400 mL of oral isotonic glucose (No NPO®, Daesang, Korea) 12 hours before anesthesia and 400 mL 2 hours before. CHL composition was standard: 12.5 g of carbohydrate per 100 mL, 12% monosaccharide, 12% disaccharide, 76% polysaccharide, 250 mOsm/kg and 50 kcal.
Study NCT02396316 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept (Eylea, BAY 86-5321)
Description: After the first aflibercept IVT injection on Day 1, subjects may receive sham injection at Week 1, and aflibercept injection at Week 5 and/or Week 9 if the re-treatment criteria are met.
Study NCT02396316 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham Injection
Description: After the first sham injection on Day 1, subjects may receive aflibercept IVT injection at Week 1, Week 5 and/or Week 9 if re-treatment criteria are met.
Study NCT02555020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Allocated to Placebo group
Description: Patients received 400 mL of oral free water (Placebo) 12 hours before anesthesia and 400 mL 2 hours before.
Study NCT02555020 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Allocated to MN NPO group,
Description: Patients received NPO from MN.
Study NCT04352465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Phase A: Subjects will be dosed 20 mg of MTX IV, once per week (total of 4 doses).
Study NCT04352465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Phase B: Subjects will be dosed 30 mg of MTX IV, once per week (total of 4 doses).
Study NCT04352465 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Phase C: Subjects will be dosed 40 mg of MTX IV, once per week (total of 4 doses).
Study NCT03974750 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Bimanual motor skill learning with the REAplan(R) rehabilitation robot
Description: REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements
Study NCT03974750 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bimanual motor skill learning with the REAplan(R) rehabilitation robot
Description: REAplan(R) rehabilitation robot : training to perform complex, coordinated, bimanual movements
Study NCT03801421 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mass continous suture with PDS
Description: The surgical incision will be treated by mass continous suture with PDS.
Study NCT03801421 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Interrupted suture with thread
Description: The surgical incision will be treated by interrupted suture with thread.
Study NCT03475264 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Lung MRI
Description: Participants will be undergoing hyperpolarized xenon and proton lung MRI
Study NCT03339505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Salovum
Description: Dietary supplement with high concentration of anti-secretory factor
Study NCT03339505 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for Salovum
Study NCT03632967 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tricinch Coil System Implantation
Description: Patients enrolled in this study with all eligibility criteria confirmed will be implanted with the TriCinch Coil System. This device offers a percutaneous treatment (access through the vein at the groin) to treat the leaking tricuspid valve.
Study NCT05106543 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients
Description: Kinesiological Taping
Study NCT05106543 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Immediate Effect Of Kinesiological Taping On Functionality In Hemiplegic Patients
Description: Kinesiological Taping
Study NCT01727986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tocilizumab [RoActemra/Actemra]
Description: 8 mg/kg or 10 mg/kg iv every 4 weeks, 104 weeks
Study NCT01973023 — intervention group
Intervention type: OTHER
Intervention: Motion analysis
Description: Motion analysis was used to assess the modifications of gait pattern in chronic spastic stroke patients regularly treated with botulinum toxin injection
Study NCT03650959 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Method of learning simple interrupted sutures with instrument tie
Description: Students will train to proficiency (defined by hand motion analysis) on simple interrupted sutures with an instrument tie via one of three different methods: faculty-led, peer tutor-led, or computer augmented self-directed learning.
Study NCT02168725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: briciclib
Study NCT03030716 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: 95% condensed proanthocyanidins from grape seed extract
Description: 0.03, 0.25, and 1.5 g 95% condensed proanthocyanidins from grape seed extract consumed three times daily for 4 weeks each
Study NCT03415984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Color retinography
Description: Color retinography
Study NCT03399448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: a cytotoxic chemotherapy agent used for lymphodepletion prior to NYCE T cells.
Study NCT03399448 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: a chemotherapy agent used for lymphodepletion prior to NYCE T cells.
Study NCT03399448 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NY-ESO-1 expression testing
Description: Testing to determine if NY-ESO-1 is expressed on tumor tissue.
Study NCT00140140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ABI-007
Description: Weekly intravenous infusions over 30 minutes.
Study NCT00140140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine
Description: Weekly intravenous infusions over 10-30 minutes, immediately after ABI-007. Vinorelbine is commercially available and was not supplied by the Sponsor.
Study NCT00718848 — intervention group
Intervention type: PROCEDURE
Intervention: Incentre nocturnal hemodialysis
Description: This is a hemodialysis schedule that consists of 3 weekly hemodialysis sessions administered overnight (8 hours/session) in-hospital.
Study NCT00718848 — intervention group
Intervention type: PROCEDURE
Intervention: Remaining on conventional hemodialysis
Description: These patients will remain on their current conventional hemodialysis schedule that consists of 4 hours/session, 3 sessions/week.
Study NCT03160599 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ketogenic diet
Description: The treatment is mainly restricted calorie ketogenic diet. KD will consist of 4:1-1:1\[fat\]:\[protein+carbohydrate\].Carbohydrate is limited to 10-30 g / day.
Study NCT03803605 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VRC07-523LS
Description: VRC07-523LS 40 mg/kg administered intravenously per series (total of 2 infusions administered)
Study NCT03803605 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat (VOR)
Description: Vorinostat 400 mg administered orally every 72 hours for 10 doses per series (A total of 20 400-mg doses administered)
Study NCT00140140 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Trastuzumab was administered to participants who had HER-2-neu positive tumors. Participants received trastuzumab by IV infusion via a vascular access device following dosing with ABI-007 and vinorelbine. During their first cycle, 4 mg/kg was administered on day 1 of that cycle as a loading dose. During subsequent weekly treatments, 2 mg/kg was administered.~Trastuzumab is commercially available and was not supplied by the Sponsor.
Study NCT03618524 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower limb hot water immersion
Description: Participants will undergo two interventions in separate visits: lower limb hot water (42 deg C) immersion up to the (1) ankles or (2) knees.
Study NCT05052450 — intervention group
Intervention type: OTHER
Intervention: Observational
Description: Patients data were collected throughout the following time
Study NCT00140140 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: During Part 1, participants followed a dosing regimen with ABI-007 and vinorelbine without G-CSF treatment. However, G-CSF was allowed for administration as necessary in accordance with commonly accepted clinical guidelines.~In Part 2, participants started G-CSF treatment in concurrence with their ABI-007 and vinorelbine treatments. G-CSF was administered to all participants on Days 2-7 of each cycle, at a dose of 5 mcg/kg. If the participant's absolute neutrophil (ANC) count was >20,000/mm\^3 on the day of anticipated chemotherapy, the site staff reduced the daily dose of G-CSF by 50% to 2.5 mcg/kg.~G-CSF is commercially available and was not supplied by the Sponsor.
Study NCT03415984 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Optical coherence tomography
Description: Optical coherence tomography
Study NCT03090373 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: UroShield
Description: The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
Study NCT03090373 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: UroShield
Description: The UroShield is an externally applied acoustic actuator which generates surface acoustic waves and transmits them along the length of the catheter. The device does not come in direct contact with the subjects.
Study NCT01831206 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Collagen cross-linking
Description: Collagen cross-linking arm will receive standard medication for corneal ulcer treatment and corneal collagen cross-linking.~Standard treatment arm will receive only standard medication.
Study NCT02129335 — intervention group
Intervention type: OTHER
Intervention: stress
Description: stress level and survival
Study NCT00513097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Prevention Program
Description: Interactive internet, computer-based activities (like games) with questions about thoughts on smoking and tobacco.
Study NCT00513097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Focus Group
Description: A total of 24 focus groups will be held relating to the topics of smoking prevention and cessation.
Study NCT00513097 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Survey
Description: On-line evaluations and questionnaires
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fludarabine phosphate
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ifosfamide
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mechlorethamine hydrochloride
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: melphalan
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mycophenolate mofetil
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: procarbazine hydrochloride
Study NCT03762434 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: mobile application
Description: Mobile app: The participants can view the Life style modification program by using the app. In addition, a membership area of the app provides individual support of self- health monitoring, goal setting of exercise plan and exercise record. A user guide of the MetS app will be provided to the participants to take home after the briefing.~Booklet : The booklet content covers 26 pages about the metabolic syndrome and risk factors, suggested life style modification tips in terms of exercise, diet, smoking, mediation and stress management.
Study NCT03407131 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Joint replacement surgery
Description: Joint replacement surgery is to replace the original joint function, so that the patient can recover the joint function as soon as possible.
Study NCT03407131 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intramedullary nail fixation
Description: Internal fixation surgery is the stable fixation of fracture, which provides the condition for the restoration of joint function.
Study NCT00596648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XL184
Description: Capsules administered orally daily
Study NCT00596648 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Tablets administered orally daily.
Study NCT04484480 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Balance training
Description: Proprioception, balance and motor coordination training using the dynamic platform - Biodex Balance System.
Study NCT02577419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Target Fortification
Study NCT02577419 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Higher Initial Concentration
Study NCT02577419 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Portagen Formula
Study NCT01624844 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geometrical calculation of dural sac volume
Description: Geometrical calculation of the lumbar dural sac volume following multilevel measurements by ultrasound imaging before spinal anesthesia
Study NCT03891927 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: extra virgin olive oil
Description: During the experimental period (3 months ), participants will be requested to consume daily dose of 30 mL (3 tablespoons) of HP-EVOO
Study NCT03282786 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: carbon dioxide insufflation during colonoscopy
Description: Use of Carbon dioxide instead of air insufflation
Study NCT02544152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lubiprostone
Description: 8 mcg administered orally twice daily (BID)
Study NCT02544152 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo, 0 mcg administered orally twice daily (BID)
Study NCT02152813 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: TENS and Task-orientated training
Description: All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine sulfate
Study NCT00574496 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinorelbine tartrate
Study NCT02152813 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: TENS and Task-orientated training
Description: All subjects will undergo 16 sessions of their assigned intervention (60 minutes, twice a week, for 8 weeks). All subjects will receive 60 minutes task-oriented lower limb training (TOT) with electrical stimulation protocol assigned concurrently:
Study NCT02092077 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TV-1106
Description: TV-1106 0.554mg, TV-1106 0.924 mg, TV-1106 1.20 mg